US Code
Part A— Drugs and Devices
§ 353a–1. Enhanced communication

(a) Submissions from State boards of pharmacyIn a manner specified by the Secretary of Health and Human Services (referred to in this section as the “Secretary”), the Secretary shall receive submissions from State boards of pharmacy—(1) describing actions taken against compounding pharmacies, as described in subsection (b); or
(2) expressing concerns that a compounding pharmacy may be acting contrary to section 353a of this title.
(b) Content of submissions from State boards of pharmacyAn action referred to in subsection (a)(1) is, with respect to a pharmacy that compounds drugs, any of the following:(1) The issuance of a warning letter, or the imposition of sanctions or penalties, by a State for violations of a State’s pharmacy regulations pertaining to compounding.
(2) The suspension or revocation of a State-issued pharmacy license or registration for violations of a State’s pharmacy regulations pertaining to compounding.
(3) The recall of a compounded drug due to concerns relating to the quality or purity of such drug.
(c) ConsultationThe Secretary shall implement subsection (a) in consultation with the National Association of Boards of Pharmacy.
(d) Notifying State boards of pharmacyThe Secretary shall immediately notify State boards of pharmacy when—(1) the Secretary receives a submission under subsection (a)(1); or
(2) the Secretary makes a determination that a pharmacy is acting contrary to section 353a of this title.

Structure US Code

US Code

Title 21— FOOD AND DRUGS

CHAPTER 9— FEDERAL FOOD, DRUG, AND COSMETIC ACT

SUBCHAPTER V— DRUGS AND DEVICES

Part A— Drugs and Devices

§ 351. Adulterated drugs and devices

§ 352. Misbranded drugs and devices

§ 353. Exemptions and consideration for certain drugs, devices, and biological products

§ 353a. Pharmacy compounding

§ 353a–1. Enhanced communication

§ 353b. Outsourcing facilities

§ 353c. Prereview of television advertisements

§ 353d. Process to update labeling for certain generic drugs

§ 354. Veterinary feed directive drugs

§ 355. New drugs

§ 355–1. Risk evaluation and mitigation strategies

§ 355–2. Actions for delays of generic drugs and biosimilar biological products

§ 355a. Pediatric studies of drugs

§ 355b. Adverse-event reporting

§ 355c. Research into pediatric uses for drugs and biological products

§ 355c–1. Report

§ 355d. Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers

§ 355e. Pharmaceutical security

§ 355f. Extension of exclusivity period for new qualified infectious disease products

§ 355g. Utilizing real world evidence

§ 355h. Regulation of certain nonprescription drugs that are marketed without an approved drug application

§ 356. Expedited approval of drugs for serious or life-threatening diseases or conditions

§ 356–1. Accelerated approval of priority countermeasures

§ 356–2. Accelerated approval Council

§ 356a. Manufacturing changes

§ 356b. Reports of postmarketing studies

§ 356c. Discontinuance or interruption in the production of life-saving drugs

§ 356c–1. Annual reporting on drug shortages

§ 356d. Coordination; task force and strategic plan

§ 356e. Drug shortage list

§ 356f. Hospital repackaging of drugs in shortage

§ 356g. Standards for regenerative medicine and regenerative advanced therapies

§ 356h. Competitive generic therapies

§ 356i. Prompt reports of marketing status

§ 356j. Discontinuance or interruption in the production of medical devices

§ 356k. Platform technologies

§ 356l. Advanced manufacturing technologies designation program

§ 357. Qualification of drug development tools

§ 358. Authority to designate official names

§ 359. Nonapplicability of subchapter to cosmetics

§ 360. Registration of producers of drugs or devices

§ 360a. Clinical trial guidance for antibiotic drugs

§ 360a–1. Clinical trials

§ 360a–2. Susceptibility test interpretive criteria for microorganisms

§ 360b. New animal drugs

§ 360b–1. Priority zoonotic animal drugs

§ 360c. Classification of devices intended for human use

§ 360c–1. Reporting

§ 360d. Performance standards

§ 360e. Premarket approval

§ 360e–1. Pediatric uses of devices

§ 360e–3. Breakthrough devices

§ 360e–4. Predetermined change control plans for devices

§ 360f. Banned devices

§ 360g. Judicial review

§ 360g–1. Agency documentation and review of significant decisions regarding devices

§ 360g–2. Third party data transparency

§ 360h. Notification and other remedies

§ 360h–1. Program to improve the device recall system

§ 360i. Records and reports on devices

§ 360j. General provisions respecting control of devices intended for human use

§ 360k. State and local requirements respecting devices

§ 360l. Postmarket surveillance

§ 360m. Accredited persons

§ 360n. Priority review to encourage treatments for tropical diseases

§ 360n–1. Priority review for qualified infectious disease products

§ 360n–2. Ensuring cybersecurity of devices